The FDA declined to approve one of biotech’s most closely watched cancer drugs
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Directly affected
- SMMT Summit Therapeutics-2.7% 13d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drugs” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drugs” (pharma and health) in this story.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SMMT | +26.12% | +17.57% | base | after close | after close | after close | after close |
| XLV | -0.28% | +0.04% | base | after close | after close | after close | after close |
| XBI | +4.20% | +3.78% | base | after close | after close | after close | after close |
| LLY | -2.25% | -0.49% | base | after close | after close | after close | after close |
| JNJ | -1.35% | -1.97% | base | after close | after close | after close | after close |
| PFE | +1.19% | +1.90% | base | after close | after close | after close | after close |
| MRK | +0.65% | -0.38% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Source: MarketWatch
Price since this story was published: Select Sector Spdr Tr (XLV)
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | -1.97% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -1.35% | final price |
| Eli Lilly (LLY) | three days earlier | -0.49% | final price |
| Eli Lilly (LLY) | five days earlier | -2.25% | final price |
| Merck (MRK) | three days earlier | -0.38% | final price |
| Merck (MRK) | five days earlier | +0.65% | final price |
| Pfizer (PFE) | three days earlier | +1.90% | final price |
| Pfizer (PFE) | five days earlier | +1.19% | final price |
| SMMT | three days earlier | +17.57% | final price |
| SMMT | five days earlier | +26.12% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.78% | final price |
| Spdr Series Trust (XBI) | five days earlier | +4.20% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.04% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -0.28% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 13 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 27 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 73 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 40 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 47 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 73 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 87 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 53 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 89 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
For “The FDA declined to approve one of biotech’s most closely watched cancer drugs,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drugs” (pharma and health) in this story
- XBI Spdr Series Trust
For “The FDA declined to approve one of biotech’s most closely watched cancer drugs,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drugs” (pharma and health) in this story
- LLY Eli Lilly
In “The FDA declined to approve one of biotech’s most closely watched cancer drugs,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story
- JNJ Johnson & Johnson
For “The FDA declined to approve one of biotech’s most closely watched cancer drugs,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 16 Nov 2026 story “The FDA declined to approve one of biotech’s most closely watched cancer drugs.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story
- MRK Merck
Merck (MRK) is linked, with no stored direction, medium confidence in the 16 Nov 2026 story “The FDA declined to approve one of biotech’s most closely watched cancer drugs.” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drugs” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
“The FDA declined to approve one of biotech’s most closely watched cancer drugs” (16 Nov 2026) reaches Select Sector Spdr Tr (XLV) through this story.
Select Sector Spdr Tr (XLV) is on the page because Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drugs” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drugs” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“The FDA declined to approve one of biotech’s most closely watched cancer drugs” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.